• To understand the prevalence of coexisting cardiovascular and kidney disease
• To provide guidance on detecting cardiovascular or kidney disease, and when to refer such patients for specialist care
• To describe the similarities and differences between guidelines on the management of cardiovascular and kidney disease
• To discuss the role of pharmacological treatment options in reducing both cardiovascular and renal risk

Speakers

Dr Jemima Scott NIHR Doctoral Research Fellow and Specialty Trainee in renal medicine, University of Bristol and North Bristol NHS Trust
Professor Chris Gale Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist, University of Leeds and Leeds Teaching Hospitals NHS Trust

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.

References:

1. Entresto (sacubitril/valsartan) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15041/smpc (accessed February 2025)
2. Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3666/smpc (accessed February 2025)
3. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification [NG238]. December 2023. Available at: https://www.nice.org.uk/guidance/ng238/chapter/Recommendations (accessed February 2025)
4. NICE. Chronic kidney dissease: Scenario: Management of chronic kidney disease. September 2024. Available at: https://cks.nice.org.uk/topics/chronic-kidney-disease/management/management-of-chronic-kidney-disease/ (accessed February 2025)
5. Saeed D et al. Cureus. 2023;15:e51362
6. Song JH et al. BMC Nephrology. 2023;24:289